How much profit has Botanix Pharmaceuticals made this year?
Botanix Pharmaceuticals has made -15.91 M AUD this year.
Botanix Pharmaceuticals Net Income 2024
Botanix Pharmaceuticals Net Income
-15.91 M AUD
Ticker
BOT.AX
ISIN
AU000000BOT2
WKN
A2ANJ5
In 2024, Botanix Pharmaceuticals's profit amounted to -15.91 M AUD, a 73.79% increase from the -9.15 M AUD profit recorded in the previous year.
The Botanix Pharmaceuticals Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2026e | 47.73 |
| 2025e | 15.91 |
| 2024e | -15.91 |
| 2023 | -9.15 |
| 2022 | -13.17 |
| 2021 | -3.33 |
| 2020 | -16.73 |
| 2019 | -17.04 |
| 2018 | -11.01 |
| 2017 | -4.77 |
| 2016 | -1.71 |
| 2015 | -1.01 |
| 2014 | -1.13 |
| 2013 | -1.85 |
| 2012 | -1.57 |
| 2011 | -1.52 |
| 2010 | -3.95 |
| 2009 | -3.04 |
| 2008 | -2.83 |
| 2007 | -3.42 |
| 2006 | -2.78 |
| 2005 | -29.76 |
| 2004 | -0.96 |
Botanix Pharmaceuticals Revenue, EBIT, Net Income AU000000BOT2 · A2ANJ5
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Botanix Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Botanix Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Botanix Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Botanix Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Botanix Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Botanix Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Botanix Pharmaceuticals’s growth potential.
Botanix Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Botanix Pharmaceuticals Revenue | Botanix Pharmaceuticals EBIT | Botanix Pharmaceuticals Net Income |
|---|---|---|---|
| 2026e | 90.09 M undefined | 0 undefined | 47.73 M undefined |
| 2025e | 30.81 M undefined | 0 undefined | 15.91 M undefined |
| 2024e | 808,000 undefined | 0 undefined | -15.91 M undefined |
| 2023 | 168,890 undefined | -12.73 M undefined | -9.15 M undefined |
| 2022 | 37,370 undefined | -15.9 M undefined | -13.17 M undefined |
| 2021 | 103,790 undefined | -10.16 M undefined | -3.33 M undefined |
| 2020 | 170,580 undefined | -24.09 M undefined | -16.73 M undefined |
| 2019 | 194,810 undefined | -21.65 M undefined | -17.04 M undefined |
| 2018 | 233,170 undefined | -12.71 M undefined | -11.01 M undefined |
| 2017 | 46,500 undefined | -4.76 M undefined | -4.77 M undefined |
| 2016 | 0 undefined | -308,400 undefined | -1.71 M undefined |
| 2015 | 43,090 undefined | -512,290 undefined | -1.01 M undefined |
| 2014 | 20,000 undefined | -2.25 M undefined | -1.13 M undefined |
| 2013 | 0 undefined | -1.66 M undefined | -1.85 M undefined |
| 2012 | 0 undefined | -1.49 M undefined | -1.57 M undefined |
| 2011 | 0 undefined | -1.51 M undefined | -1.52 M undefined |
| 2010 | 0 undefined | -1.99 M undefined | -3.95 M undefined |
| 2009 | 10,000 undefined | -3.15 M undefined | -3.04 M undefined |
| 2008 | 40,000 undefined | -3.14 M undefined | -2.83 M undefined |
| 2007 | 50,000 undefined | -3.67 M undefined | -3.42 M undefined |
| 2006 | 90,000 undefined | -3.07 M undefined | -2.78 M undefined |
| 2005 | 350,000 undefined | -2.89 M undefined | -29.76 M undefined |
| 2004 | 2.19 M undefined | 760,000 undefined | -960,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.19 M AUD | 760,000 AUD | -960,000 AUD |
| 2005 | 350,000 AUD | -2.89 M AUD | -29.76 M AUD |
| 2006 | 90,000 AUD | -3.07 M AUD | -2.78 M AUD |
| 2007 | 50,000 AUD | -3.67 M AUD | -3.42 M AUD |
| 2008 | 40,000 AUD | -3.14 M AUD | -2.83 M AUD |
| 2009 | 10,000 AUD | -3.15 M AUD | -3.04 M AUD |
| 2010 | 0 AUD | -1.99 M AUD | -3.95 M AUD |
| 2011 | 0 AUD | -1.51 M AUD | -1.52 M AUD |
| 2012 | 0 AUD | -1.49 M AUD | -1.57 M AUD |
| 2013 | 0 AUD | -1.66 M AUD | -1.85 M AUD |
| 2014 | 20,000 AUD | -2.25 M AUD | -1.13 M AUD |
| 2015 | 43,090 AUD | -512,290 AUD | -1.01 M AUD |
| 2016 | 0 AUD | -308,400 AUD | -1.71 M AUD |
| 2017 | 46,500 AUD | -4.76 M AUD | -4.77 M AUD |
| 2018 | 233,170 AUD | -12.71 M AUD | -11.01 M AUD |
| 2019 | 194,810 AUD | -21.65 M AUD | -17.04 M AUD |
| 2020 | 170,580 AUD | -24.09 M AUD | -16.73 M AUD |
| 2021 | 103,790 AUD | -10.16 M AUD | -3.33 M AUD |
| 2022 | 37,370 AUD | -15.9 M AUD | -13.17 M AUD |
| 2023 | 168,890 AUD | -12.73 M AUD | -9.15 M AUD |
| 2024e | 808,000 AUD | 0 AUD | -15.91 M AUD |
| 2025e | 30.81 M AUD | 0 AUD | 15.91 M AUD |
| 2026e | 90.09 M AUD | 0 AUD | 47.73 M AUD |
Botanix Pharmaceuticals stock margins AU000000BOT2 · A2ANJ5
The Botanix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Botanix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Botanix Pharmaceuticals.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Botanix Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Botanix Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Botanix Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Botanix Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Botanix Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Botanix Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Botanix Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Botanix Pharmaceuticals Margin History
| Botanix Pharmaceuticals Gross margin | Botanix Pharmaceuticals Profit margin | Botanix Pharmaceuticals EBIT margin | Botanix Pharmaceuticals Profit margin |
|---|---|---|---|
| 2026e | -1,160.52 % | 0 % | 52.98 % |
| 2025e | -1,160.52 % | 0 % | 51.64 % |
| 2024e | -1,160.52 % | 0 % | -1,968.92 % |
| 2023 | -1,160.52 % | -7,537.34 % | -5,420.08 % |
| 2022 | -20,176.61 % | -42,557.35 % | -35,244.18 % |
| 2021 | 308.31 % | -9,792.36 % | -3,212.26 % |
| 2020 | -1,160.52 % | -14,121.51 % | -9,808.13 % |
| 2019 | -1,160.52 % | -11,113.65 % | -8,746.58 % |
| 2018 | -1,160.52 % | -5,449.95 % | -4,722.65 % |
| 2017 | -1,160.52 % | -10,235.83 % | -10,264.73 % |
| 2016 | -1,160.52 % | 0 % | 0 % |
| 2015 | -1,160.52 % | -1,188.88 % | -2,354.47 % |
| 2014 | -1,160.52 % | -11,250 % | -5,650 % |
| 2013 | -1,160.52 % | 0 % | 0 % |
| 2012 | -1,160.52 % | 0 % | 0 % |
| 2011 | -1,160.52 % | 0 % | 0 % |
| 2010 | -1,160.52 % | 0 % | 0 % |
| 2009 | -1,160.52 % | -31,500 % | -30,400 % |
| 2008 | -1,160.52 % | -7,850 % | -7,075 % |
| 2007 | -1,160.52 % | -7,340 % | -6,840 % |
| 2006 | -1,160.52 % | -3,411.11 % | -3,088.89 % |
| 2005 | -1,160.52 % | -825.71 % | -8,502.86 % |
| 2004 | -1,160.52 % | 34.7 % | -43.84 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -1,160.52 % | 34.7 % | -43.84 % |
| 2005 | -1,160.52 % | -825.71 % | -8,502.86 % |
| 2006 | -1,160.52 % | -3,411.11 % | -3,088.89 % |
| 2007 | -1,160.52 % | -7,340 % | -6,840 % |
| 2008 | -1,160.52 % | -7,850 % | -7,075 % |
| 2009 | -1,160.52 % | -31,500 % | -30,400 % |
| 2010 | -1,160.52 % | 0 % | 0 % |
| 2011 | -1,160.52 % | 0 % | 0 % |
| 2012 | -1,160.52 % | 0 % | 0 % |
| 2013 | -1,160.52 % | 0 % | 0 % |
| 2014 | -1,160.52 % | -11,250 % | -5,650 % |
| 2015 | -1,160.52 % | -1,188.88 % | -2,354.47 % |
| 2016 | -1,160.52 % | 0 % | 0 % |
| 2017 | -1,160.52 % | -10,235.83 % | -10,264.73 % |
| 2018 | -1,160.52 % | -5,449.95 % | -4,722.65 % |
| 2019 | -1,160.52 % | -11,113.65 % | -8,746.58 % |
| 2020 | -1,160.52 % | -14,121.51 % | -9,808.13 % |
| 2021 | 308.31 % | -9,792.36 % | -3,212.26 % |
| 2022 | -20,176.61 % | -42,557.35 % | -35,244.18 % |
| 2023 | -1,160.52 % | -7,537.34 % | -5,420.08 % |
| 2024e | -1,160.52 % | 0 % | -1,968.92 % |
| 2025e | -1,160.52 % | 0 % | 51.64 % |
| 2026e | -1,160.52 % | 0 % | 52.98 % |
Botanix Pharmaceuticals Aktienanalyse
What does Botanix Pharmaceuticals do?
Botanix Pharmaceuticals Ltd is an Australian company specializing in the research and development of innovative therapies based on synthetic cannabinoids. The company was founded in 2014 by a team of experts and is headquartered in Perth, Western Australia. The history of Botanix Pharmaceuticals began with the discovery of the medical properties of cannabinoids derived from the hemp plant. Cannabinoids have a wide therapeutic potential, ranging from pain and inflammation relief to the treatment of seizure disorders and anxiety. Botanix Pharmaceuticals utilizes these properties to develop innovative product candidates that have high efficacy and tolerability. The business model of Botanix Pharmaceuticals is based on the concept of targeted treatment for diseases and conditions where traditional therapies are insufficient or cause unwanted side effects. The company develops and produces medications based on synthetic cannabinoids that target specific disease states and indications. Botanix Pharmaceuticals specializes in two areas. Firstly, it focuses on the development of topical products, such as ointments and creams, that are applied to the skin. These products are particularly effective in treating skin conditions such as acne or psoriasis. Secondly, the company is working on the development of medications for the treatment of internal conditions such as epilepsy or chronic obstructive pulmonary disease (COPD). In the field of topical products, Botanix Pharmaceuticals has already achieved significant success. The company has a promising pipeline of product candidates for various applications, including acne, psoriasis, atopic dermatitis, and bacterial infections. One promising drug candidate is BTX 1503, which was developed for the treatment of severe acne. It contains the synthetic cannabinoid BTX 1308, which possesses anti-inflammatory and antimicrobial properties. BTX 1503 has already demonstrated high efficacy and tolerability in clinical studies. In the field of internal conditions, Botanix Pharmaceuticals collaborates closely with leading institutions and research facilities to develop innovative therapies for seizure disorders and COPD. One promising product candidate is BTX 1801, which was developed for the treatment of severe epilepsy. BTX 1801 contains the synthetic cannabinoid BTX 1204, which has shown high efficacy and tolerability in the treatment of seizures. Botanix Pharmaceuticals is an innovative company that develops highly effective and tolerable medications based on synthetic cannabinoids. The company has already achieved remarkable success in a short period and has established itself as a leading player in the industry. With its pipeline of promising product candidates and its close collaboration with renowned research institutions, Botanix Pharmaceuticals is well-positioned to develop further innovative therapies in the future. Botanix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Botanix Pharmaceuticals's Profit Margins
The profit margins of Botanix Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Botanix Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Botanix Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Botanix Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Botanix Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Botanix Pharmaceuticals stock
How has the profit developed compared to last year?
The profit has increased by 73.79% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Botanix Pharmaceuticals publish its earnings?
Botanix Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Botanix Pharmaceuticals?
The profits of Botanix Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Botanix Pharmaceuticals?
You can learn more about the earnings of Botanix Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Botanix Pharmaceuticals pay?
Over the past 12 months, Botanix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Botanix Pharmaceuticals is expected to pay a dividend of 0 AUD.
What is the dividend yield of Botanix Pharmaceuticals?
The current dividend yield of Botanix Pharmaceuticals is .
When does Botanix Pharmaceuticals pay dividends?
Botanix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, October, April, November.
How secure is the dividend of Botanix Pharmaceuticals?
Botanix Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Botanix Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Botanix Pharmaceuticals located?
Botanix Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Botanix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Botanix Pharmaceuticals from 10/25/1996 amounting to 0.048 AUD, you needed to have the stock in your portfolio before the ex-date on 10/3/1996.
When did Botanix Pharmaceuticals pay the last dividend?
The last dividend was paid out on 10/25/1996.
What was the dividend of Botanix Pharmaceuticals in the year 2023?
In the year 2023, Botanix Pharmaceuticals distributed 0 AUD as dividends.
In which currency does Botanix Pharmaceuticals pay out the dividend?
The dividends of Botanix Pharmaceuticals are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Botanix Pharmaceuticals
Our stock analysis for Botanix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Botanix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Botanix Pharmaceuticals Revenue
- Botanix Pharmaceuticals Net Income
- Botanix Pharmaceuticals P/E
- Botanix Pharmaceuticals P/S
- Botanix Pharmaceuticals EBIT
- Botanix Pharmaceuticals Dividend
- Botanix Pharmaceuticals Stocks
- Botanix Pharmaceuticals Market capitalization
- Botanix Pharmaceuticals Debt
- Botanix Pharmaceuticals Liabilities
- Botanix Pharmaceuticals Equity
- Botanix Pharmaceuticals AAQS
- Botanix Pharmaceuticals Employees
- Botanix Pharmaceuticals ROE
- Botanix Pharmaceuticals ROA
- Botanix Pharmaceuticals ROCE
